Filing Flows › Pure Bioscience (PURE) › Q4 FY25
Pure Bioscience (PURE) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Oct 29, 2025
Pure Bioscience (PURE) reported revenue of $763K for the fourth quarter fiscal 2025 (Q4 FY25), +62% from a year earlier and +56% from the quarter before. Operating margin was -44.0%, net loss $332K (43.5% of revenue).
Pure Bioscience, Q4 FY25: revenue $763K (+62% year over year), operating margin -44.0%, net loss $332K, operating cash flow −$456K. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $763K | +56% | +62% |
| Operating profit | −$336K | — | — |
| Net earnings | −$332K | — | — |
| Operating cash flow | −$456K | — | — |
What changed
Revenue was $763K in Q4 FY25, up 62% year over year and up 56% from the previous quarter. PURE Hard Surface was the largest line at 99% of revenue.
Gross margin was 61.3%, up 3.1 points from a year earlier. Operating costs exceeded revenue by $336K, an operating margin of -44.0%. Operating expenses fell 17% while revenue rose 62%. The quarter ended with a net loss of $332K, narrower than the previous quarter's $580K loss.
Operating cash flow was −$456K. Non-cash charges added back $30K of share-based compensation. Working capital and other items used $154K.
Questions
What was Pure Bioscience's revenue in the fourth quarter fiscal 2025?
Pure Bioscience (PURE) reported revenue of $763K for the fourth quarter fiscal 2025 (Q4 FY25), +62% from a year earlier and +56% from the quarter before.
Was Pure Bioscience profitable in the fourth quarter fiscal 2025?
Operating loss was $336K (-44.0% of revenue) and net loss $332K.
Source: Pure Bioscience 10-K on SEC EDGAR.